These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 37833562)

  • 1. p53 dry gene powder enhances anti-cancer effects of chemotherapy against malignant pleural mesothelioma.
    Muramatsu N; Ichikawa M; Katagiri T; Taguchi Y; Hatanaka T; Okuda T; Okamoto H
    Gene Ther; 2024 Mar; 31(3-4):119-127. PubMed ID: 37833562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 modeling as a route to mesothelioma patients stratification and novel therapeutic identification.
    Tian K; Bakker E; Hussain M; Guazzelli A; Alhebshi H; Meysami P; Demonacos C; Schwartz JM; Mutti L; Krstic-Demonacos M
    J Transl Med; 2018 Oct; 16(1):282. PubMed ID: 30316293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells.
    Rao M; Atay SM; Shukla V; Hong Y; Upham T; Ripley RT; Hong JA; Zhang M; Reardon E; Fetsch P; Miettinen M; Li X; Peer CJ; Sissung T; Figg WD; De Rienzo A; Bueno R; Schrump DS
    Clin Cancer Res; 2016 Mar; 22(5):1197-210. PubMed ID: 26459178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of inhalable gene transfection as a novel gene therapy for non-small cell lung cancer and malignant pleural mesothelioma.
    Ichikawa M; Muramatsu N; Matsunaga W; Ishikawa T; Okuda T; Okamoto H; Gotoh A
    Sci Rep; 2022 May; 12(1):8634. PubMed ID: 35606391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth
    Laszlo V; Valko Z; Kovacs I; Ozsvar J; Hoda MA; Klikovits T; Lakatos D; Czirok A; Garay T; Stiglbauer A; Helbich TH; Gröger M; Tovari J; Klepetko W; Pirker C; Grusch M; Berger W; Hilberg F; Hegedus B; Dome B
    Clin Cancer Res; 2018 Aug; 24(15):3729-3740. PubMed ID: 29724868
    [No Abstract]   [Full Text] [Related]  

  • 6. Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma.
    Kopecka J; Salaroglio IC; Righi L; Libener R; Orecchia S; Grosso F; Milosevic V; Ananthanarayanan P; Ricci L; Capelletto E; Pradotto M; Napoli F; Di Maio M; Novello S; Rubinstein M; Scagliotti GV; Riganti C
    Lung Cancer; 2018 Jun; 120():34-45. PubMed ID: 29748013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Restored expression of the MYO18B gene suppresses orthotopic growth and the production of bloody pleural effusion by human malignant pleural mesothelioma cells in SCID mice.
    Edakuni N; Ikuta K; Yano S; Nakataki E; Muguruma H; Uehara H; Tani M; Yokota J; Aizawa H; Sone S
    Oncol Res; 2006; 16(5):235-43. PubMed ID: 17294804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BAP1 gene mutations in Egyptian patients with advanced sporadic malignant pleural mesothelioma (MPM): relation with clinical outcomes and survival.
    Bahnasy AA; El-Din RS; Sabri NA; Abdel-Rahman CA; Bastawisy AE
    Cancer Genet; 2018 Dec; 228-229():83-92. PubMed ID: 30553477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. UHRF1 Is a Novel Druggable Epigenetic Target in Malignant Pleural Mesothelioma.
    Reardon ES; Shukla V; Xi S; Gara SK; Liu Y; Straughan D; Zhang M; Hong JA; Payabyab EC; Kumari A; Richards WG; De Rienzo A; Hassan R; Miettinen M; Xi L; Raffeld M; Uechi LT; Li X; Wang R; Chen H; Hoang CD; Bueno R; Schrump DS
    J Thorac Oncol; 2021 Jan; 16(1):89-103. PubMed ID: 32927122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JQ1, a BET Inhibitor, Synergizes with Cisplatin and Induces Apoptosis in Highly Chemoresistant Malignant Pleural Mesothelioma Cells.
    Zanellato I; Colangelo D; Osella D
    Curr Cancer Drug Targets; 2018; 18(8):816-828. PubMed ID: 28669341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased sensitivity to apoptosis upon endoplasmic reticulum stress-induced activation of the unfolded protein response in chemotherapy-resistant malignant pleural mesothelioma.
    Xu D; Liang SQ; Yang H; Lüthi U; Riether C; Berezowska S; Marti TM; Hall SRR; Bruggmann R; Kocher GJ; Schmid RA; Peng RW
    Br J Cancer; 2018 Jul; 119(1):65-75. PubMed ID: 29921948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma.
    Linton A; Cheng YY; Griggs K; Schedlich L; Kirschner MB; Gattani S; Srikaran S; Chuan-Hao Kao S; McCaughan BC; Klebe S; van Zandwijk N; Reid G
    Br J Cancer; 2014 Jan; 110(2):510-9. PubMed ID: 24327015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High RRM1 Expression Is Associated with Adverse Outcome in Patients with Cisplatin/Vinorelbine-treated Malignant Pleural Mesothelioma.
    Zimling ZG; Santoni-Rugiu E; Bech C; Sørensen JB
    Anticancer Res; 2015 Dec; 35(12):6731-8. PubMed ID: 26637889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition.
    Srinivasan G; Sidhu GS; Williamson EA; Jaiswal AS; Najmunnisa N; Wilcoxen K; Jones D; George TJ; Hromas R
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):861-867. PubMed ID: 28756516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison between the effects of over-expression of miRNA-16 and miRNA-34a on cell cycle progression of mesothelioma cell lines and on their cisplatin sensitivity.
    Pinelli S; Alinovi R; Corradi M; Poli D; Cavallo D; Pelosi G; Ampollini L; Goldoni M; Mozzoni P
    Cancer Treat Res Commun; 2021; 26():100276. PubMed ID: 33338854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists.
    Urso L; Cavallari I; Silic-Benussi M; Biasini L; Zago G; Calabrese F; Conte PF; Ciminale V; Pasello G
    Oncotarget; 2017 Jul; 8(27):44232-44241. PubMed ID: 28562336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro.
    Hoda MA; Pirker C; Dong Y; Schelch K; Heffeter P; Kryeziu K; van Schoonhoven S; Klikovits T; Laszlo V; Rozsas A; Ozsvar J; Klepetko W; Döme B; Grusch M; Hegedüs B; Berger W
    Mol Cancer Ther; 2016 Oct; 15(10):2357-2369. PubMed ID: 27512118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoxia Inducible Factor-1α Inhibition in Von Hippel Lindau-mutant Malignant Pleural Mesothelioma Cells.
    Shukuya T; Oyanagi J; Serizawa M; Watanabe M; Yamamoto N; Koh Y
    Anticancer Res; 2020 Apr; 40(4):1867-1874. PubMed ID: 32234874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-occurring Mutations of Tumor Suppressor Genes,
    Tranchant R; Quetel L; Tallet A; Meiller C; Renier A; de Koning L; de Reynies A; Le Pimpec-Barthes F; Zucman-Rossi J; Jaurand MC; Jean D
    Clin Cancer Res; 2017 Jun; 23(12):3191-3202. PubMed ID: 28003305
    [No Abstract]   [Full Text] [Related]  

  • 20. Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma.
    Tsao A; Nakano T; Nowak AK; Popat S; Scagliotti GV; Heymach J
    Semin Oncol; 2019 Apr; 46(2):145-154. PubMed ID: 31280996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.